Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference
March 16, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, March 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that Chief Development...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2017 Financial and Operating Results
March 02, 2018 07:30 ET
|
Reata Pharmaceuticals, Inc.
ADVANCED TWO PROGRAMS INTO PIVOTAL TRIALS IN 2017 CARDINAL PHASE 2 RETAINED BENEFIT DATA EXPECTED 3Q18 DATA FROM FIRST PHOENIX COHORT EXPECTED 2H18 IRVING, Texas, March 02, 2018 (GLOBE NEWSWIRE)...
Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
March 01, 2018 17:14 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, March 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced top-line data from the...
Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
February 27, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
First patient enrolled for all cohorts of PHOENIX First data from PHOENIX expected 2H18 Retained benefit analysis from Phase 2 portion of CARDINAL expected 3Q18 IRVING, Texas, Feb. 27, 2018 ...
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
February 12, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
Progressive loss of kidney function is a validated independent predictor of death and hospitalization in PAH patients Increases in eGFR from bardoxolone methyl treatment were maintained for two years...
Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology
January 18, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the digital...
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
December 11, 2017 07:30 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of...
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
November 13, 2017 07:30 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced financial results for the...
Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
November 06, 2017 07:30 ET
|
Reata Pharmaceuticals, Inc.
Conference call to update bardoxolone renal program today at 8:30am ET IRVING, Texas, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a...
Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting
November 03, 2017 11:00 ET
|
Reata Pharmaceuticals, Inc.
Met primary endpoint of change in EGFR at 12 weeks (P<0.000000001) 73% of patients had improvement in stage of CKD Bardoxolone was well tolerated without any safety concerns Conference call with...